FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--Oct 3, 2025-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 30,000 shares of KalVista common stock on October 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the first day a closing price is reported following the grant date.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)